Fierce Pharma January 5, 2024
The attempted merger between leading biopharma data provider IQVIA and pharma ad specialist DeepIntent has been put on ice after continued scrutiny from the U.S. government.
In 2022, IQVIA attempted to acquire Propel, the owner of DeepIntent, though the financial details of the proposed deal remain unknown. However, last summer, the Federal Trade Commission (FTC) intervened and blocked the transaction.
The FTC argued that the acquisition would inevitably grant IQVIA a dominant position in healthcare product advertising, particularly for prescription drugs targeted at doctors and other healthcare professionals. The company is one of the world’s largest holders of pharmaceutical sales, prescription and patient record data, something that could, given its reach, allow it to monopolize the pharma advertising market.
Just...
Today's Sponsors
Today's Sponsor